Edition:
United States

Seattle Genetics Inc (SGEN.O)

SGEN.O on Nasdaq

59.13USD
22 Nov 2017
Change (% chg)

$0.08 (+0.14%)
Prev Close
$59.05
Open
$59.06
Day's High
$59.58
Day's Low
$58.32
Volume
476,011
Avg. Vol
987,853
52-wk High
$72.75
52-wk Low
$45.31

Latest Key Developments (Source: Significant Developments)

TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
Tuesday, 14 Nov 2017 10:00am EST 

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​.‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​.  Full Article

SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)
Thursday, 9 Nov 2017 12:40pm EST 

Nov 9 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF).SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​.SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE FOR ADCETRIS WAS DECEMBER 16, 2017​.  Full Article

Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin
Wednesday, 8 Nov 2017 08:00am EST 

Nov 8 (Reuters) - Seattle Genetics Inc :Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer.Primary objective of trial is to assess safety and tolerability of Enfortumab Vedotin in combination with CPI therapy​.  Full Article

Seattle Genetics submits supplemental license application for Adcetris
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Seattle Genetics Inc :Seattle genetics submits supplemental biologics license application to FDA for Adcetris (brentuximab vedotin) in frontline advanced hodgkin lymphoma.  Full Article

Seattle Genetics reports Q3 earnings $0.34/shr
Thursday, 26 Oct 2017 04:02pm EDT 

Oct 26 (Reuters) - Seattle Genetics Inc :Seattle Genetics reports third quarter 2017 financial results.Q3 earnings per share $0.34.Q3 revenue $135.3 million versus I/B/E/S view $112.8 million.Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Seattle Genetics Inc sees FY 2017 ‍revenues from collaboration and license agreements $90 million to $100 million​.Seattle Genetics Inc sees ‍fy 2017 royalty revenues $60 million to $65 million​.  Full Article

Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin
Tuesday, 10 Oct 2017 08:00am EDT 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>::Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.Seattle Genetics Inc - ‍companies also plan to initiate a combination trial of enfortumab vedotin with CPI therapy in late 2017​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 06:20am EDT 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Seattle Genetics receives FDA breakthrough therapy designation for lumphoma drug
Monday, 2 Oct 2017 06:45am EDT 

Oct 2 (Reuters) - Seattle Genetics Inc :Seattle Genetics receives FDA breakthrough therapy designation for adcetris® (brentuximab vedotin) in frontline advanced hodgkin lymphoma.Seattle Genetics-‍submission of supplemental biologics license application for adcetris in frontline advanced hodgkin lymphoma planned before 2017 end.  Full Article

FDA accepts supplemental biologics license application and grants priority review for adcetris in cutaneous t-cell lymphoma
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - Seattle Genetics Inc ::FDA accepts supplemental biologics license application and grants priority review for adcetris® (brentuximab vedotin) in cutaneous t-cell lymphoma.Says ‍FDA granted priority review for application and pdufa target action date is december 16, 2017​.Says ‍adcetris is currently not approved for treatment of ctcl​.  Full Article

Seattle Genetics to buy Bothell plant from Bristol-Myers Squibb
Tuesday, 1 Aug 2017 04:00pm EDT 

Aug 1 (Reuters) - Bristol-Myers Squibb Co :Seattle Genetics announces purchase of Bothell manufacturing facility from Bristol-Myers Squibb.Seattle Genetics - ‍signed definitive agreements to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in Bothell, Washington​.Seattle Genetics - ‍intends to offer employment to manufacturing facility's current employees​.Seattle Genetics - plans to utilize facility primarily for antibody production for current and future pipeline programs​.Seattle Genetics - ‍company intends to offer employment to manufacturing facility's current employees​.  Full Article

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)